Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: Virbac

Market Cap 286.94Cr 330.65Cr 264.5Cr 247.83Cr 463.06Cr 32TCr 472.7Cr 3.16TCr 1.22TCr 15TCr 1.24TCr 1.21TCr 53TCr P/E Ratio 2026 *
17.1x
P/E Ratio 2027 * 15.2x
Enterprise Value 299.04Cr 344.6Cr 275.65Cr 258.28Cr 482.58Cr 33TCr 492.63Cr 3.29TCr 1.27TCr 16TCr 1.29TCr 1.27TCr 55TCr EV / Sales 2026 *
1.93x
EV / Sales 2027 * 1.77x
Free-Float
49.03%
Yield 2026 *
0.51%
Yield 2027 * 0.6%
1 day+6.04%
1 month+6.04%
3 months-6.49%
6 months-6.49%
Current year-6.49%
1 month 408
Extreme 408
408
Current year 384.75
Extreme 384.75
408
1 year 384.75
Extreme 384.75
436.32
3 years 288
Extreme 288
436.32
5 years 288
Extreme 288
436.32
10 years 131
Extreme 131
436.32
Manager TitleAgeSince
Chief Executive Officer 46 01/09/2025
Chief Executive Officer 50 27/09/2024
Chief Operating Officer 64 01/01/2022
Director TitleAgeSince
Chairman 61 01/04/2006
Director/Board Member 68 28/07/2010
Director/Board Member 65 05/09/2017
Change 5-day change 1-year change 3-year change Capi.($)
+6.04%-.--% - - 331.53Cr
+0.14%+2.36%-51.06%-50.83% 3.41TCr
+5.16%-2.67%+68.54%+156.94% 1.14TCr
-0.79%-7.64%+4.37%+28.88% 460.03Cr
-1.08%+3.47%+58.22%+19.30% 194.51Cr
+3.11%+6.62%-32.03%+1.36% 161.36Cr
+0.26%-5.39%+28.17%+127.68% 126.48Cr
-2.39%-5.75%-28.16%-12.83% 103.55Cr
-2.07%-2.07%-6.36%-44.56% 101.89Cr
-0.85%+4.32%-4.63%-21.41% 95Cr
Average +0.77%+0.24%+4.12%+22.73% 643.65Cr
Weighted average by Cap. +1.38%+1.38%-15.19%+5.45%

Financials

2026 *2027 *
Net sales 154.64Cr 178.19Cr 142.54Cr 133.56Cr 249.55Cr 17TCr 254.75Cr 1.7TCr 658.32Cr 8.22TCr 668.94Cr 654.52Cr 29TCr 163.95Cr 188.93Cr 151.13Cr 141.61Cr 264.58Cr 18TCr 270.09Cr 1.8TCr 697.97Cr 8.72TCr 709.23Cr 693.95Cr 30TCr
Net income 17Cr 19Cr 15Cr 14Cr 27Cr 1.84TCr 28Cr 183.66Cr 71Cr 888.36Cr 72Cr 71Cr 3.09TCr 19Cr 22Cr 18Cr 16Cr 31Cr 2.1TCr 31Cr 209.14Cr 81Cr 1.01TCr 82Cr 81Cr 3.52TCr
Net Debt 12Cr 14Cr 11Cr 10Cr 20Cr 1.34TCr 20Cr 133.04Cr 52Cr 643.51Cr 52Cr 51Cr 2.24TCr 2.65Cr 3.05Cr 2.44Cr 2.29Cr 4.28Cr 292.31Cr 4.36Cr 29Cr 11Cr 140.9Cr 11Cr 11Cr 489.92Cr
Logo Virbac
Virbac specializes in the research, production and marketing of veterinary medicines. Net sales break down by family of products as follows: - pet medications (60.7%): pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips; - livestock medications (39.3%): pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc. Net sales are distributed geographically as follows: Europe (41.6%), Latin America (15.2%), North America (13.6%), India/Africa/Middle East (12.2%), Eastern Asia (10.5%) and Pacific (6.9%).
Employees
6,442
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
342.50EUR
Average target price
412.88EUR
Spread / Average Target
+20.55%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!